AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T15:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Wed 21 May 25, 11:00 AMPresenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
Tue 20 May 25, 11:00 AMClene to Present at the Emerging Growth Conference
Mon 14 Apr 25, 12:30 PMClene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Wed 12 Mar 25, 12:00 PMClene to Present at the 37TH Annual Roth Conference
Thu 06 Mar 25, 01:30 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -26.17300M | -39.40000M | -49.50400M | -29.91800M | -10.16800M |
| Minority interest | - | - | - | - | - |
| Net income | -26.17300M | -39.40000M | -49.50400M | -15.27900M | -9.74000M |
| Selling general administrative | 9.23M | 13.31M | 14.42M | 16.94M | 18.81M |
| Selling and marketing expenses | - | 1.03M | 1.05M | - | - |
| Gross profit | 0.16M | 0.27M | 0.53M | 0.45M | 0.43M |
| Reconciled depreciation | 1.50M | 1.65M | 1.59M | 1.02M | 0.95M |
| Ebit | -23.08300M | -35.33600M | -44.94600M | -45.33000M | -45.27600M |
| Ebitda | -21.58800M | -33.69100M | -43.24100M | -45.07300M | -47.51600M |
| Depreciation and amortization | 1.50M | 1.65M | 1.71M | 0.26M | -2.24000M |
| Non operating income net other | - | - | - | 21.79M | 40.68M |
| Operating income | -23.08300M | -33.09300M | -40.54000M | -45.33000M | -45.27600M |
| Other operating expenses | 23.28M | 33.44M | 41.19M | 45.80M | 46.00M |
| Interest expense | 2.68M | 4.06M | 4.56M | 3.30M | 0.87M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | -0.42800M |
| Interest income | 0.22M | 0.86M | 1.39M | - | - |
| Net interest income | -3.47200M | -3.96000M | -4.55600M | -4.06900M | -4.05300M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | 1.54M | -14.63900M | -0.42800M |
| Total revenue | 0.20M | 0.34M | 0.65M | 0.47M | 0.72M |
| Total operating expenses | 23.24M | 33.37M | 41.07M | 45.78M | 45.71M |
| Cost of revenue | 0.04M | 0.07M | 0.12M | 0.03M | 0.29M |
| Total other income expense net | -3.09000M | -6.30700M | -8.96400M | 15.41M | 35.11M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -26.17300M | -39.40000M | -40.38500M | -29.91800M | -9.74000M |
| Net income applicable to common shares | - | - | - | -29.91800M | -9.74000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 18.13M | 27.34M | 52.34M | 44.49M | 63.06M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.75M | 3.54M | 2.48M | 5.65M | 0.17M |
| Total liab | 35.72M | 36.19M | 38.95M | 41.26M | 50.47M |
| Total stockholder equity | -17.59200M | -8.85700M | 13.39M | 3.24M | 12.60M |
| Deferred long term liab | - | - | - | - | 18.10M |
| Other current liab | 5.00M | 5.10M | 3.72M | 3.86M | 3.61M |
| Common stock | 0.00100M | 0.00100M | 0.01M | 0.00700M | 0.00600M |
| Capital stock | 0.00100M | 0.00100M | 0.01M | 0.00700M | 0.00600M |
| Retained earnings | -308.29600M | -282.12300M | -242.72300M | -193.21900M | -163.30100M |
| Other liab | - | - | - | 2.56M | 20.89M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 0.06M | 0.06M |
| Cash | 5.19M | 12.15M | 28.82M | 18.33M | 50.29M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 10.78M | 10.29M | 25.33M | 13.86M | 6.03M |
| Current deferred revenue | - | 2.67M | 0.00000M | - | - |
| Net debt | 16.48M | 8.69M | 3.34M | 13.49M | -26.24600M |
| Short term debt | 4.88M | 1.28M | 20.11M | 6.98M | 0.49M |
| Short long term debt | 4.07M | 0.36M | 19.50M | 6.42M | - |
| Short long term debt total | 21.67M | 20.84M | 32.16M | 31.82M | 24.04M |
| Other stockholder equity | 290.53M | 273.19M | 255.90M | 196.25M | 175.66M |
| Property plant equipment | - | - | - | 15.24M | 5.17M |
| Total current assets | 8.98M | 16.16M | 38.85M | 29.20M | 54.58M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 3.24M | 12.60M |
| Short term investments | - | 0.00000M | 6.18M | 4.98M | - |
| Net receivables | 0.00000M | 0.39M | 1.34M | 0.19M | 1.61M |
| Long term debt | 13.54M | 15.43M | 7.15M | 19.25M | 14.48M |
| Inventory | 0.04M | 0.07M | 0.04M | 0.04M | 0.04M |
| Accounts payable | 0.89M | 1.24M | 1.50M | 3.01M | 1.92M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.17M | 0.07M | 0.20M | 0.20M | 0.23M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00700M | 0.00600M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -193.21900M | -163.30100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.06M | 0.06M | 0.06M | 0.06M | 0.06M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 9.15M | 11.18M | 13.49M | 15.30M | 8.48M |
| Capital lease obligations | 4.06M | 5.06M | 5.51M | 6.15M | 4.96M |
| Long term debt total | - | - | - | - | 14.48M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00000M | 6.32M | 7.00M | -4.98500M | -1.33200M |
| Change to liabilities | - | - | - | 0.54M | 2.33M |
| Total cashflows from investing activities | -0.03900M | 6.32M | -1.49900M | -10.16400M | -1.33200M |
| Net borrowings | 1.12M | -10.89600M | 0.27M | 5.61M | 19.46M |
| Total cash from financing activities | 11.52M | -1.52900M | 42.16M | 17.25M | 27.11M |
| Change to operating activities | - | - | - | -1.68300M | 0.04M |
| Net income | -26.17300M | -39.40000M | -49.50400M | -29.91800M | -9.74000M |
| Change in cash | -6.96600M | -16.66600M | 10.49M | -31.95600M | -8.92900M |
| Begin period cash flow | 12.21M | 28.88M | 18.39M | 50.35M | 59.27M |
| End period cash flow | 5.25M | 12.21M | 28.88M | 18.39M | 50.35M |
| Total cash from operating activities | -18.54600M | -21.32600M | -30.17100M | -39.01100M | -34.62400M |
| Issuance of capital stock | 10.40M | 9.24M | 53.42M | 11.46M | 9.25M |
| Depreciation | 1.50M | 1.65M | 1.71M | 1.02M | 0.95M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.03M | -0.03100M | 0.00600M | -0.00200M | 0.15M |
| Change to account receivables | 0.06M | 0.08M | 0.05M | -0.14000M | -0.02800M |
| Sale purchase of stock | - | - | - | 11.77M | 7.80M |
| Other cashflows from financing activities | 1.50M | 0.12M | -0.20000M | 5.92M | 18.02M |
| Change to netincome | - | - | - | 8.35M | 10.66M |
| Capital expenditures | 0.04M | 0.01M | 0.33M | 5.18M | 1.33M |
| Change receivables | - | - | - | -0.14000M | -0.02800M |
| Cash flows other operating | - | - | - | -19.71700M | -38.95800M |
| Exchange rate changes | - | - | - | - | -0.08500M |
| Cash and cash equivalents changes | - | - | - | -31.92600M | -8.92900M |
| Change in working capital | -3.35300M | 3.21M | -0.19100M | -1.54000M | 1.00M |
| Stock based compensation | 6.38M | 7.95M | 9.12M | 8.51M | 12.38M |
| Other non cash items | 3.10M | 5.26M | 8.70M | -17.08500M | -37.59500M |
| Free cash flow | -18.58500M | -21.34100M | -30.50100M | -44.19000M | -35.95600M |
Sector: Consumer Defensive Industry: Packaged Foods
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLNN Clene Inc. |
-0.06 1.02% | 5.83 | - | - | 372.19 | 7.83 | 447.55 | -1.1292 |
| NSRGF Nestle SA |
- -% | 98.25 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
1.83 1.88% | 99.15 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| GPDNF Danone S.A |
1.67 2.22% | 77.05 | 25.33 | 17.39 | 1.97 | 2.55 | 1.88 | 11.70 |
| DANOY Danone PK |
0.20 1.31% | 15.49 | 24.23 | 17.64 | 1.88 | 2.57 | 1.88 | 11.70 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
6550 South Millrock Drive, Salt Lake City, UT, United States, 84121
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert Etherington MBA | CEO, Pres & Director | 1967 |
| Mr. Mark G. Mortenson | Co-Founder & Chief Science Officer | 1958 |
| Dr. Robert Glanzman M.D. | Chief Medical Officer | 1957 |
| Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA | Chief Financial Officer | 1968 |
| Mr. Jerry Miraglia J.D. | Gen. Counsel & Corp. Sec. | NA |
| Mr. Michael T. Hotchkin | Chief Devel. Officer | NA |
| Ms. Mary Anne Mcneil | Head of HR | NA |
| Dr. Tae Heum Jeong D. Mgt. | Consultant | 1971 |
| Mr. Robert Etherington MBA | CEO, President & Director | 1967 |
| Mr. Morgan R. Brown CPA, M.B.A. | Chief Financial Officer | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...